Zota Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 09-12-2024
- Paid Up Capital ₹ 0.30 M
as on 09-12-2024
- Company Age 21 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -19.04%
(FY 2022)
- Profit -74.52%
(FY 2022)
- Ebitda -29.89%
(FY 2022)
- Net Worth 3.88%
(FY 2022)
- Total Assets 1.75%
(FY 2022)
About Zota Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Arumugam Olaganathan and Kottai Ranganathan serve as directors at the Company.
- CIN/LLPIN
U24231TN2003PTC050612
- Company No.
050612
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Zota Pharmaceuticals Private Limited offer?
Zota Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Digestive System Drugs & Medicines, Antacid Drugs, Brain & Nervous System Drugs, Antiepileptic Drugs, Anti Inflammatory Drugs, Common Disease Medicines, Pharmaceutical Tablets, Respiratory System Drugs.
Who are the key members and board of directors at Zota Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kottai Ranganathan  | Director | 28-Mar-2003 | Current |
| Arumugam Olaganathan | Director | 28-Mar-2006 | Current |
Financial Performance of Zota Pharmaceuticals.
Zota Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 19.04% decrease. The company also saw a substantial fall in profitability, with a 74.52% decrease in profit. The company's net worth moved up by a moderate rise of 3.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zota Pharmaceuticals?
Unlock access to Zota Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Kinesis Pharmaceuticals Private LimitedActive 30 years 9 months
Arumugam Olaganathan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zota Pharmaceuticals?
Unlock and access historical data on people associated with Zota Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zota Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zota Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
